Engflag

Repevax

Quick links to important sections

Repevax

Selected form

Repevax_DA

Method of action: Vaccine

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Repevax

Property Description
Active Ingredient Diphtheria, Tetanus, Acellular Pertussis Antigens, Inactivated Poliovirus
Form Suspension for Injection
Pharmacological Class Immunological Agent (Combination Vaccine)
Common Use Booster Protection against Four Infectious Diseases
Origin Biological/Derived

What Type of Vaccine is Repevax and What is its General Purpose?

Repevax is an immunological agent classified as a tetravalent combination vaccine specifically intended for active immunization as a booster dose. Its general purpose is to maintain long-term protection against four serious infectious diseases: Diphtheria, Tetanus, Pertussis (Whooping cough), and Poliomyelitis (Polio). This combination of four antigens into a single suspension for injection is a strategy for simplifying the boosting schedule. The vaccine is typically indicated for persons from 3 years of age onwards, whose immunity from their initial childhood vaccination series naturally diminishes over time.

What is the Composition of Repevax?

The composition of Repevax adheres to the Tdap-IPV designation, indicating a specific formulation featuring reduced antigen content. The active ingredients include highly purified Diphtheria toxoid and Tetanus toxoid, a multi-component acellular Pertussis preparation, and inactivated Poliovirus (Types 1, 2, and 3). Supplied as a sterile suspension, this adsorbed vaccine includes an adjuvant, such as Aluminium phosphate, for enhancing the overall immune response. This formulation is distinctive because the lower concentration of diphtheria and tetanus components is appropriate for booster use in older individuals.

How Does Repevax Work to Provide Protection?

Repevax provides active protection by introducing harmless, inactivated components of the bacteria and viruses to the immune system, thereby stimulating the body's natural defenses. The vaccine's mechanism relies on generating immune memory and specific antibodies without causing the actual disease. By safely reinforcing the immunological recognition of these pathogens, Repevax rapidly restores robust defenses. This targeted action ensures the body is prepared for immediate response, effectively preventing the four target infections upon subsequent real-world exposure.

Regulatory References

  1. NIH Study on Reduced Antigen Content

What side effects are possible with Repevax?

Possible Side Effects and Safety Information

Adverse reactions associated with Repevax (Diphtheria, Tetanus, Acellular Pertussis, and Inactivated Poliovirus vaccine) are formally classified by frequency and System-Organ-Class (SOC) in regulatory documentation. The most frequently observed events are typically localized, transient, and occur shortly after administration.

Frequency Classification Common Adverse Reactions (Examples)
Very Common (ge 1/10) Headache, fatigue, malaise, pain at the injection site.
Common (ge 1/100 to < 1/10) Fever, myalgia (muscle pain), nausea, vomiting, diarrhoea, injection site swelling and redness.
Uncommon (ge 1/1,000 to < 1/100) Dizziness, chills, paraesthesia (tingling sensation).

Serious adverse reactions are reported with Frequency Not Known from post-marketing surveillance, including severe immediate hypersensitivity events such as Anaphylactic reactions. Rare neurological disorders, including Brachial neuritis and Guillain-Barré Syndrome (GBS), have also been documented in this context.

Safety data specifies that local adverse reactions typically occur within the first 48 hours, while systemic reactions generally occur within the first 3 days after administration. Regulatory documentation notes that the frequency of certain local reactions, such as pain and swelling, may be higher in adults compared to adolescents.

Administration of Repevax is generally restricted where there is a known severe hypersensitivity to any vaccine component or a life-threatening reaction following a previous dose of a diphtheria, tetanus, pertussis, or polio vaccine. These safety characteristics structure the risk profile as defined in official government regulatory labeling.

Overdose and Emergency Response

Overdose and when to seek help

Overdose scope

Domain Regulatory Statement
Documented overdose presentations: Official regulatory labeling does not define a specific clinical syndrome resulting from the administration of an excessive dose. Overdosage is primarily associated with a potential increase in the frequency or severity of documented adverse reactions.
Physiological systems affected (as stated in label): Life-threatening symptoms requiring urgent attention affect the respiratory system (e.g., difficulty in breathing, blueness of the lips/tongue) and the circulatory system (e.g., low blood pressure causing dizziness or collapse).
Dose-related or exposure-related factors (if applicable): No specific toxic dose level is documented.
Population-specific overdose notes (if applicable): No specific population-related overdose severity or management considerations for an excess dose are explicitly documented in the official labeling.
Emergency-response statements (as written in official documents): Facilities for the management of anaphylaxis must be available at the time of administration.
When immediate medical help is required (label-derived phrasing only): You must consult a doctor IMMEDIATELY if signs of a serious allergic reaction occur after leaving the place of injection, including swelling of the face or throat, difficulty breathing, or sudden dizziness.

Overdose classifications (high-level)

Classification Regulatory Statement
Severity classification (as defined in official documents): Serious allergic reactions (anaphylaxis) are classified as a very rare possibility (may affect up to 1 in 10,000 people).
Regulatory basis (EMA / FDA / etc.): Information is derived from the Summary of Product Characteristics (SmPC) / Patient Information Leaflet (PIL).
Overdose-context constraints (as defined in official documents): Management is symptomatic and supportive treatment; no specific antidote is known.

Resulting overdose structure

Official overdose statements:

  • The official labeling does not specify symptoms for a distinct overdose syndrome (administration of an excessive dose).
  • The key emergency scenario requiring immediate medical attention is a serious allergic reaction, characterized by difficulty in breathing, facial/throat swelling, or low blood pressure.
  • Management for an excess dose is limited to supportive treatment, as no specific antidote is available.

Connection to the overall overdose profile (2–4 sentences):

Regulatory documents define the overdose profile by stating the absence of a specific toxic manifestation following an excessive dose, directing prescribers to observe for increased adverse reactions. This profile mandates that the critical help-seeking condition is the onset of a life-threatening, serious allergic reaction—an event that requires immediate consultation with a doctor. The management instructions are strictly constrained to observation and supportive measures.

Therapeutic Uses of Repevax

What Repevax Treats: Main Uses and Benefits

Repevax (Tdap-IPV) is an immunological booster whose therapeutic role is not to treat active infection, but to support the continuation of protection against four severe diseases. The benefit is prophylactic, aiming to establish protection against conditions associated with severe complications.

The vaccine is indicated for active immunization against diphtheria, tetanus, pertussis, and poliomyelitis in persons from 3 years of age as a booster following primary immunization.

Symptom Domains and Use Scenarios

Repevax supports defense against debilitating symptom clusters that include neuromuscular spasms (like lockjaw), paralysis risks, and profound respiratory distress and airway compromise. The vaccine is used in several key contexts: as part of routine booster schedules for older children and adults; as an urgent measure for post-exposure prophylaxis following a Tetanus-prone injury; and during pregnancy to generate passive protection against Pertussis for the newborn. This may assist with protection against infections that cause symptoms that create noticeable physiological strain and interfere with daily functioning.

Quick Fact: Relief for Respiratory Stress The Pertussis component is relevant for managing symptom clusters that may become intense or disruptive, specifically violent, uncontrollable coughing fits associated with severe respiratory distress in infants.

Eligibility and Restrictions for Use

Who Can and Cannot Use Repevax?

The eligibility for Repevax is strictly defined by regulatory authorities and centers on age, allergy history, and current health status. It is indicated for use in persons from 3 years of age and older as a booster vaccine.

Absolute Contraindications

Repevax must not be used in individuals who have:

  • A known hypersensitivity to the active substances (diphtheria, tetanus, pertussis, or poliomyelitis vaccines) or any other components, including residual substances from manufacture (e.g., neomycin, formaldehyde).
  • Experienced an encephalopathy of unknown origin within seven days following a previous pertussis-containing vaccine.
  • Are children under 3 years of age.

Conditional Use and Restrictions

Administration must be postponed if the person has an acute severe febrile illness or an unstable/progressive neurological disorder, such as uncontrolled epilepsy, until the condition stabilizes.

Repevax may be given to pregnant individuals during the second or third trimester to provide passive pertussis protection to the newborn. Vaccination is also recommended for HIV-infected or chronically immunodeficient persons, though the immune response may be limited. Patients with coagulation disorders may require a careful subcutaneous injection due to bleeding risk.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Pharmacodynamic and Immunological Interactions

The official interaction profile for this vaccine is governed by effects on the immune system, not typical drug metabolism. The most significant interaction involves concurrent use of immunosuppressive medicinal products. Regulatory documents state that co-administration with substances like high-dose corticosteroids or chemotherapeutic agents may result in a suboptimal or reduced protective immune response. Because the vaccine’s function relies on stimulating the body's defenses, any therapy that weakens the immune system may diminish the expected level of protection.

Administration Restrictions and Constraints

Administration is subject to mandatory timing rules and conditions. The process must be postponed in persons suffering from an acute severe febrile illness until the condition has fully resolved. Furthermore, administration is contraindicated if a person has a known hypersensitivity to any of the trace residual substances used during manufacturing, such as formaldehyde or the antibiotics polymyxin B and neomycin. The official profile also restricts administration following an encephalopathy of unknown origin occurring within seven days of a prior pertussis-containing vaccine.

Pharmacokinetic and Non-Medicinal Interactions

The official labeling does not document interactions involving drug metabolism. There are no documented interactions that involve CYP enzymes, drug transporters, food, alcohol, or herbal products.

Mechanism of Action

How Repevax Works

Repevax initiates an Active Immunization process by presenting four distinct antigens (toxoids, viral particles, acellular components) to the host immune system. The overall mechanism operates through establishing long-term Immunological Memory and generating a pool of circulating antibodies.

Toxin and Viral Neutralization Cascades

This domain covers the core protective action: the generated IgG antibodies physically bind to and inactivate the specific toxic and viral targets. This extracellular blockade functions by intercepting Diphtheria Toxin, thereby preserving cellular protein synthesis; it similarly interferes with Tetanospasmin binding to inhibitory neurotransmission pathways in the CNS and executes Viraemia Blockade by intercepting the Poliovirus before it accesses the central nervous system.

Antigen Recognition and Mechanistic Constraints

The mechanism begins with the aluminum adjuvant promoting rapid uptake of antigens by Antigen-Presenting Cells (APCs), stimulating B-lymphocytes and T-lymphocytes. This systemic activation results in an amplified anamnestic (booster) response upon subsequent antigen exposure. However, the immunity generated by the acellular pertussis component primarily leads to non-sterilizing protection, meaning the mechanism limits the pathogen's activity and reduces colonization density but may not entirely prevent pathogen presence at the mucosal surface.

Dosage and Administration Information

How Repevax is Used: Official Administration and Dosing Principles

Repevax is administered strictly according to official protocols defining the route, dose, frequency, and preparation necessary for its authorized use as a booster vaccine.

Administration Route and Dosing

Category Official Instruction
Route of Administration The primary method is intramuscular (IM) injection, usually into the deltoid muscle. Deep subcutaneous injection may be used only for individuals with a bleeding disorder.
Standard Dose The prescribed dose is a single injection of 0.5 mL. This fixed dose is used for all recipients from 3 years of age onwards.
Prohibited Routes Intravascular (into a blood vessel), intradermal, and gluteal administration are officially prohibited.

Usage Patterns and Context

Repevax is not intended for primary immunization but only for maintaining protection against the four diseases.

Category Official Instruction
Frequency and Schedule Administered as a booster dose following a complete primary series, with repeated use intervals determined by national guidelines, often at intervals of 5 to 10 years.
Preparation Before use, the syringe containing the suspension must be shaken vigorously until it forms a homogeneous, cloudy white suspension.
Age Rules Approved for use in persons from 3 years of age onwards. It is also recommended for pregnant women during the second or third trimester to confer passive protection to the newborn.
Co-administration If given concurrently with other approved vaccines, each injection must be delivered into a separate limb.

These instructions structure the use of Repevax as a standardized, single-event booster administered via a specific route and volume, strictly adhering to requirements across all approved age groups.

Recent Clinical Evidence

Research evidence / Overview of Studies for Repevax

Research Evidence for Routine Booster Immunization

The clinical evaluation of Repevax for routine booster use has been primarily studied through short-term, multicenter Randomized Controlled Trials (RCTs) in older children, adolescents, and healthy adults. Researchers were examining the combination vaccine's capacity to induce an immune response (immunogenicity).

The main outcomes monitored were Seroprotection Rates (SPR) and Geometric Mean Titers (GMT), which are laboratory measurements of antibody concentrations against the four disease components. Trials reported high measurements of these antibody levels, typically taken at one month after vaccination. What remains uncertain is the long-term clinical efficacy—the ability to prevent actual disease cases over many years—because clinical trials use antibody levels as a surrogate marker rather than directly measuring disease prevention outcomes.

Evidence for Use Following a Tetanus-Prone Injury (Post-Exposure)

Research has explored the use of Repevax in a very specific, short-term context: management after an injury where there is a risk of Tetanus. Phase IIIb Randomized Controlled Trials were conducted in healthy adults to see if the Tetanus component of the combined vaccine achieved the non-inferiority criteria compared to the monovalent Tetanus vaccine.

Studies monitored the anti-Tetanus antibody concentration at very short intervals. The findings described patterns showing that the combined vaccine's antibody levels were comparable to the monovalent Tetanus vaccine within the predefined research criteria. The study evaluation is primarily based on achieving a predefined antibody level, not on the clinical prevention of Tetanus disease following an injury.

Research on Maternal Immunization for Newborn Protection

Studies have been applied in the research context of maternal vaccination to explore the transfer of antibodies against Pertussis to infants. Findings indicate that a high rate of Pertussis antibody transfer to the fetus occurs following maternal vaccination. Although blunting (interference with the infant’s own primary antibody response) was observed in some studies, it was not observed to diminish the infant's own antibody response to their primary series during the vulnerable first few months of life.

Frequently Asked Questions (FAQ)

Common questions about Repevax (FAQ)

Q: Can Repevax be administered to me if I have a history of Guillain-Barré Syndrome (GBS)?

If a person has a history of Guillain-Barré Syndrome (GBS) that occurred within six weeks of receiving a previous tetanus-containing vaccine, the decision to administer Repevax is based on careful consideration of the potential benefits and possible risks by a healthcare provider. For other patients, regulatory documents contain no specific contraindication based on a history of GBS.

Q: How is the Tdap-IPV formulation different from the standard DTaP vaccine given to infants?

The Tdap-IPV formulation differs from the DTaP vaccine primarily in the dose of antigen it contains. The Tdap formulation (the diphtheria and pertussis part of Repevax) has a reduced dose of diphtheria and pertussis antigens. The lower concentration of antigens is described in official documents as appropriate for booster use in older individuals.

Q: What specific strains of poliovirus does Repevax protect against?

Repevax is designed to protect against the three types of poliovirus that cause paralytic disease. The specific strains of inactivated poliovirus included in the vaccine are officially listed as Types 1 (Mahoney), Type 2 (MEF-1), and Type 3 (Saukett).

Q: What are the components of the acellular pertussis part of the vaccine?

The acellular pertussis component, which provides protection against Whooping Cough, is multi-component. Regulatory documents specify that it is composed of several purified antigens, including Pertussis toxoid, Filamentous haemagglutinin (FHA), Pertactin (PRN), and Fimbriae types 2 and 3.

Q: If I'm taking immunosuppressive drugs, can I still get the shot, and will it be effective?

For individuals receiving immunosuppressive drugs or who have chronic immunodeficiency, the immune response to Repevax may be limited or suboptimal. While vaccination is generally recommended for persons with chronic immunodeficiency, official information mentions that if possible, vaccination may be postponed until immunosuppressive treatment is finished.

Q: What is the mechanism by which the aluminum adjuvant enhances the immune response?

The aluminum adjuvant is included in Repevax to help stimulate the body's immune system. Official information indicates the adjuvant works by facilitating the uptake of the vaccine antigens by immune cells and by activating local inflammatory cells. The process aids in generating a robust immunological memory.

Q: What should I do if I miss my scheduled booster dose?

Official immunization guidance indicates that the vaccine can typically be administered later without restarting the primary series. Any catch-up schedule is determined by a healthcare provider based on official national recommendations, often regardless of the interval since the last dose of a similar vaccine.

Q: Does Repevax have any effect on blood clotting or INR levels?

Official product labeling does not document that Repevax has a direct effect on blood clotting factors or INR levels. However, caution is advised for the injection route in individuals with known coagulation (blood clotting) disorders due to the risk of bruising or bleeding at the injection site.

Q: Can I drink alcohol immediately after getting the Repevax shot?

The official product information does not document any direct interaction between the vaccine and alcohol. While there is no formal restriction on moderate consumption, excessive consumption is generally cautioned against after vaccination as it may potentially interfere with the immune system or intensify common side effects.

Q: What should I do with the empty syringe or any leftover vaccine?

Regulatory information specifies that unused or expired Repevax must not be disposed of in household waste or through wastewater. It is necessary to consult with a pharmacist or healthcare provider for guidance on the proper disposal of the empty syringe and any leftover product, in accordance with local pharmaceutical waste requirements.

How should Repevax be stored and disposed of?

Storage and Disposal Requirements

Repevax must be stored under controlled conditions to maintain the vaccine's integrity, as mandated by official labeling.

  • Storage Temperature: The vaccine requires cold storage and must be kept in a refrigerator at a temperature between 2°C and 8°C.
  • Protection Requirements: It is strictly prohibited to freeze the vaccine; any product that has been frozen must be discarded. The container must be kept in its original outer carton to protect the contents from light.
  • Child Safety: Repevax must be stored out of the sight and reach of children.
  • Expiration: The medicine must not be used after the expiry date shown on the packaging.

Disposal

The disposal of unused or expired Repevax must not be conducted through household waste or wastewater. Discarding the product must be done in accordance with local requirements for pharmaceutical waste. Individuals are directed to consult a pharmacist for guidance on proper disposal procedures.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

flagPortugal

Equivalent of Repevax found in:

A-Z Index: